A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Clinical trial NCT03459846 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03459846
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urinary Bladder Neoplasms

Start date: 2018-03-16
Primary completion: 2020-10-15
Enrollment: 154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.